Association of molecular subtypes in bladder cancer with response to neoadjuvant chemotherapy, progression, and survival
Considering the molecular subtype of muscle-invasive bladder cancer (MIBC) based on differences in tumor RNA expression can improve the ability of an existing tumor biomarker such as the COXEN score to predict which patients’ tumors are likely to respond to chemotherapy given before surgery. Individual molecular subtypes, however, were not associated with significant differences in patients’ overall survival (OS) or progression-free survival (PFS) times.
Those are the conclusions from a secondary analysis of data from the S1314 clinical trial, a large study in patients with MIBC that was conducted by the SWOG Cancer Research Network, a clinical trials group funded by ...















